Diagnósticos da América S.A Market Cap ($723.42 Million)
Market Cap & Net Worth: Diagnósticos da América S.A (DASA3)
Diagnósticos da América S.A market cap. Diagnósticos da América S.A (SA:DASA3) has a market capitalization of $723.42 Million (R$3.69 Billion) as of November 6, 2026. Listed on the SA stock exchange, this Brazil-based company holds position #10093 globally and #100 in its home market, demonstrating a -7.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Diagnósticos da América S.A's stock price R$2.95 by its total outstanding shares 1249774542 (1.25 Billion). Also see cash flow conversion of Diagnósticos da América S.A for how efficiently the company converts equity into cash flow.
Diagnósticos da América S.A Market Cap History (2015–2026)
Diagnósticos da América S.A market cap history from 2015 to 2026. Data shows change from $2.32 Billion to $723.42 Million (-9.09% CAGR). Check DASA3 stock price and chart for real-time trading data and today's change.
Index Memberships
Diagnósticos da América S.A is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
SAO PAULO SE IGCX INDEX
IGCX
|
$566.75 Billion | 0.13% | #60 of 155 |
Weight: Diagnósticos da América S.A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Diagnósticos da América S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Diagnósticos da América S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore DASA3 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.03x
Diagnósticos da América S.A's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.32 Billion | $2.79 Billion | $23.81 Million | 0.83x | 97.38x |
| 2016 | $4.07 Billion | $3.04 Billion | $94.74 Million | 1.34x | 42.99x |
| 2017 | $6.35 Billion | $3.40 Billion | $131.44 Million | 1.87x | 48.34x |
| 2018 | $6.30 Billion | $3.93 Billion | $184.38 Million | 1.60x | 34.17x |
| 2019 | $13.88 Billion | $4.36 Billion | $124.78 Million | 3.18x | 111.22x |
| 2020 | $17.43 Billion | $7.04 Billion | -$150.80 Million | 2.48x | N/A |
| 2021 | $8.22 Billion | $10.42 Billion | -$226.57 Million | 0.79x | N/A |
| 2022 | $3.37 Billion | $13.13 Billion | -$386.92 Million | 0.26x | N/A |
| 2023 | $2.36 Billion | $14.25 Billion | -$1.17 Billion | 0.17x | N/A |
| 2024 | $465.93 Million | $15.32 Billion | -$1.20 Billion | 0.03x | N/A |
Competitor Companies of DASA3 by Market Capitalization
Companies near Diagnósticos da América S.A in the global market cap rankings as of November 6, 2026. Also see DASA3 total asset value for a full breakdown of the balance sheet.
Key companies related to Diagnósticos da América S.A by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #86 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #146 globally with a market cap of $159.88 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #478 globally with a market cap of $55.90 Billion USD ( CN¥382.02 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #510 globally with a market cap of $52.43 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #86 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $676.94 |
| #146 | Danaher Corporation | NYSE:DHR | $159.88 Billion | $226.34 |
| #478 | WuXi AppTec Co Ltd | SHG:603259 | $55.90 Billion | CN¥154.46 |
| #510 | Natera Inc | NASDAQ:NTRA | $52.43 Billion | $363.76 |
Market Capitalization of Diagnósticos da América S.A (2015–2026)
Market capitalization of Diagnósticos da América S.A from 2015 to today. Between 2015 and today, Diagnósticos da América S.A's market cap moved from $2.32 Billion to $ 723.42 Million, with a yearly change of -9.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | R$723.42 Million | -35.02% |
| 2025 | R$1.11 Billion | +138.95% |
| 2024 | R$465.93 Million | -80.25% |
| 2023 | R$2.36 Billion | -29.93% |
| 2022 | R$3.37 Billion | -59.02% |
| 2021 | R$8.22 Billion | -52.87% |
| 2020 | R$17.43 Billion | +25.63% |
| 2019 | R$13.88 Billion | +120.26% |
| 2018 | R$6.30 Billion | -0.84% |
| 2017 | R$6.35 Billion | +56.02% |
| 2016 | R$4.07 Billion | +75.63% |
| 2015 | R$2.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Diagnósticos da América S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $723.42 Million USD |
| MoneyControl | $723.42 Million USD |
| MarketWatch | $723.42 Million USD |
| marketcap.company | $723.42 Million USD |
| Reuters | $723.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Diagnósticos da América S.A
Diagnósticos da América S.A., together with its subsidiaries, provides diagnostic and hospital services in Brazil and Argentina. It operates through Hospitals and Oncology; Diagnostics and Care Coordination; and International Diagnostics segments. The company offers outpatient doctors; medical and outpatient services; diagnostic support assistants for private patients or partner companies; care c… Read more